NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Unfortunately for Dr Mullholand his IPI-GLIO failed failed because the SOC arm did so well.

Overall Survival (Arm A vs B): median OS 22.7 vs 26.4 months, HR 1.223 (60% CI 0.986-1.516, p=0.431); 18 month OS 53% (60%CI 48-58%) vs 64% (56-70%).

Maybe the problem in his trial was that after the SOC patients progressed they elected to usu Yervoy on their own. Yea, that must be it.

Truly amazing how again and again we see trials where the randomized comparison fails but a comp to ECA's would indicate success.